$CNBX

CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals is a clinical-stage pharmaceutical company based in Bethesda, Maryland. It focuses on discovering and developing cannabinoid-based products and technologies for cancer treatment. Its lead product candidate, Cannabics SR, is a sustained-release oral capsule being developed for patients with advanced cancer and cancer anorexia-cachexia syndrome. RCC-33 is an oral capsule or solution under development for colorectal cancer. CNBX’s core activities include drug discovery, intellectual property development and regulatory work for its candidates. It does not manufacture, distribute or sell products. Its stated business model is to pursue FDA regulatory pathways and clinical studies, then seek commercial opportunities such as agreements with larger pharmaceutical companies. The company’s research and development has been conducted in a government-licensed laboratory facility in Israel.

No enriched coverage for $CNBX in the last 7 days.

No SEC Form 4 filings for $CNBX in the last 30 days.

See all $CNBX insider activity →

CNBX sentiment & insider activity

What's driving CNBX

  • CNBX Pharmaceuticals saw an 88.89% rise at a share price of $0.00, which may reflect low liquidity or a data anomaly.

    Benzinga · May 28, 2025

  • CannaBiX Technologies (CNBX) shows a somewhat bullish outlook, supported by recent positive price action.

    Benzinga · May 20, 2025

  • CNBX shows bullish sentiment with potential for short-term appreciation.

    Benzinga · May 15, 2025

  • CannaBiDiol Biosciences (CNBX) exhibits positive sentiment with potential for gains.

    Benzinga · May 12, 2025

  • CNBX Pharmaceuticals experienced a significant 15% rise, indicating strong investor interest potentially driven by recent developments or news.

    Benzinga · May 8, 2025

AlphAI scores every news story that mentions CNBX with an AI model for sentiment and relevance, and aggregates insider trades from CNBX Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CNBX

Score

Related tickers